Transparency Disclosures

We are committed to leading the way in adopting and applying the highest standards of good governance, ethics and transparency in our industry.

EFPIA Disclosure Code Reports

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. EFPIA believes that interactions between the pharmaceutical industry and healthcare professionals have a profound and positive influence on the quality of patient treatment and the value of future research and therefore, requires transparency to these interactions through the EFPIA Disclosure Code. Country specific Industry Associations, in the UK the Association of the British Pharmaceutical Industry (ABPI) and in Ireland the Irish Pharmaceutical Healthcare Association (IPHA), transposed this Code into local Codes which went into effect on January 1, 2015.

Takeda supports the principles of transparency put forth by EFPIA and is committed to ensuring we meet the highest degree of integrity expected by our patients, healthcare professionals, healthcare organisations and other stakeholders.

UK Disclosure Reports are available on the ABPI Disclosure UK website

Ireland Disclosure Reports are available on the IPHA Transfer of Value website

Contact Us:

Takeda Disclosure Reports - Cco.smbx.gb-UKCompliance@takeda.com

Patient Group and Members of the Public Disclosures

Patient Groups – or patient advocacy groups and patient organisations – are important partners for Takeda. Our aim is to forge trusting, mutually-beneficial relationships with patient groups. To build and maintain this trust, we are committed to understanding and addressing unmet needs in the patient community. We support patient organisations in our therapeutic areas through sponsorships, grants and donations.

In keeping with our commitment to ensure responsible business practices, Takeda believes transparency in our funding decisions is vital to building and maintaining trust with our stakeholders.

Donations and Grants

Takeda UK and Takeda Products Ireland Ltd wishes to work in partnership with the NHS / HSE and Healthcare Professionals (HCPs) and is pleased to consider financial donation/grant requests that will directly benefit the NHS / HSE and its patients. This also includes requests from patient groups or other charitable causes. All requests must meet the regulatory requirements of the Association of British Pharmaceutical Industry (ABPI) Code of Practice and Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice.

Download Guidance Notes and Grant Request Form.

In line with the requirements of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, Takeda UK has submitted all relevant data regarding donations and grants made to UK healthcare organisations from 2015 onwards to the ABPI central disclosure platform. Please visit the ABPI website for further information.

Clinical Trials and Results

Takeda Clinical Study Transparency Policy

Takeda is committed to transparency and integrity in its clinical research in keeping with our corporate philosophy of Takeda-ism. Takeda has been and continues to be committed to complying with all laws and regulations related to the registration and disclosure of Takeda-sponsored clinical study information.

Takeda is dedicated to the timely registration of clinical studies, communication of clinical study result summaries, and publication of our company sponsored clinical research. Following a change in the Association of the British Pharmaceutical Industry's (ABPI) Code of Practice, companies are now obliged to publish all clinical trial results within one year of marketing authorisation and publically register new trials within 21 days of the first patient being enrolled. Takeda is pleased to meet these requirements.

In addition, Takeda supports pharmaceutical industry's joint initiatives relating to increased clinical trial transparency, including the principles and joint positions of IFPMA, EFPIA, JPMA, and PhRMA relative to the disclosure and publication of results from clinical studies for approved medicines. Takeda is committed to complying with the PhRMA/EFPIA principles and to sharing, upon request from qualified scientific and medical researchers for legitimate research purposes, anonymised patient-level clinical study data, study-level results summaries, and protocols from clinical studies for approved medicines and indications. Takeda is actively working to establish processes to accept and review data sharing requests consistent with this commitment, while also safeguarding patient privacy and confidentiality.

Legal Notice - Clinical Study Registrations and Results Disclosures

Takeda makes all reasonable efforts to provide current protocol information and study result summaries for Takeda-sponsored clinical studies. These study results pertain to the main objectives and key safety information in the form of summary data based on a single study population. These data do not include patient-level data.

Although these single study result summaries may be helpful to patients, physicians, and researchers, they may not reflect the overall benefits and risks associated with Takeda's medicines, which are based on the entirety of the information available for a given medicine. So while patients are welcome to view the study result summaries provided via the below link, only qualified healthcare professionals can determine if a specific medicine is appropriate for a particular patient. If you are a patient and have questions regarding any information available, or a particular medical condition, you should consult a qualified healthcare professional.

When making prescribing decisions, healthcare professionals should always refer to the specific labelling information approved in the patient's country or region rather than information provided by Takeda. The information provided by Takeda is not intended to promote or otherwise commercialise (directly or indirectly) Takeda medicines or any off-label or unapproved uses.

Click here to read more about Takeda's commitment to clinical trial transparency

## Clinical Trials and Results ### Takeda Clinical Study Transparency Policy Takeda is committed to transparency and integrity in its clinical research in keeping with our corporate philosophy of Takeda-ism. Takeda has been and continues to be committed to complying with all laws and regulations related to the registration and disclosure of Takeda-sponsored clinical study information. Takeda is dedicated to the timely registration of clinical studies, communication of clinical study result summaries, and publication of our company sponsored clinical research. Following a change in the Association of the British Pharmaceutical Industry's (ABPI) Code of Practice, companies are now obliged to publish all clinical trial results within one year of marketing authorisation and publically register new trials within 21 days of the first patient being enrolled. Takeda is pleased to meet these requirements. In addition, Takeda supports pharmaceutical industry's joint initiatives relating to increased clinical trial transparency, including the principles and joint positions of IFPMA, EFPIA, JPMA, and PhRMA relative to the disclosure and publication of results from clinical studies for approved medicines. Takeda is committed to complying with the PhRMA/EFPIA principles and to sharing, upon request from qualified scientific and medical researchers for legitimate research purposes, anonymised patient-level clinical study data, study-level results summaries, and protocols from clinical studies for approved medicines and indications. Takeda is actively working to establish processes to accept and review data sharing requests consistent with this commitment, while also safeguarding patient privacy and confidentiality. ### Legal Notice - Clinical Study Registrations and Results Disclosures Takeda makes all reasonable efforts to provide current protocol information and study result summaries for Takeda-sponsored clinical studies. These study results pertain to the main objectives and key safety information in the form of summary data based on a single study population. These data do not include patient-level data. Although these single study result summaries may be helpful to patients, physicians, and researchers, they may not reflect the overall benefits and risks associated with Takeda's medicines, which are based on the entirety of the information available for a given medicine. So while patients are welcome to view the study result summaries provided via the below link, only qualified healthcare professionals can determine if a specific medicine is appropriate for a particular patient. If you are a patient and have questions regarding any information available, or a particular medical condition, you should consult a qualified healthcare professional. When making prescribing decisions, healthcare professionals should always refer to the specific labelling information approved in the patient's country or region rather than information provided by Takeda. The information provided by Takeda is not intended to promote or otherwise commercialise (directly or indirectly) Takeda medicines or any off-label or unapproved uses. [Click here to read more about Takeda's commitment to clinical trial transparency](https://clinicaltrials.takeda.com/)

EXA/GB/CORP/0418 Date of Preparation: August 2025

Transparency Disclosures | Takeda UK